• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在中度至重度症状性干眼症患者中使用lifitegrast进行六个月治疗:一项回顾性病历审查。

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review.

作者信息

Atallah Richard Teofilo, Castanos Maria Virginia, Najac Richard, Donnenfeld Eric

机构信息

Rutgers New Jersey Medical School , Newark, NJ, USA.

Department of Research, Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.

出版信息

Clin Ophthalmol. 2019 Jun 19;13:1033-1037. doi: 10.2147/OPTH.S191635. eCollection 2019.

DOI:10.2147/OPTH.S191635
PMID:31354236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6590901/
Abstract

PURPOSE

To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients.

SETTING

Retrospective chart analysis.

METHOD

A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris.

RESULTS

Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed.

CONCLUSION

Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye.

摘要

目的

评估5%利非司特滴眼液对有症状的干眼患者6个月的治疗效果。

背景

回顾性病历分析。

方法

对168例(111例女性和57例男性)患有慢性干眼疾病症状并接受5%利非司特滴眼液治疗6个月的患者进行回顾性病历审查。收集的症状数据包括眼干、流泪、眼痛、视力波动、异物感、瘙痒、沙砾感、烧灼感以及适用时的隐形眼镜不耐受情况的改善。收集的临床体征包括浅层点状角膜炎、角膜荧光素染色、结膜充血和泪液碎屑的变化。

结果

每天两次使用5%利非司特滴眼液治疗6个月可显著改善患者报告的大多数干眼症状。在大多数接受审查的患者中,角膜和结膜染色以及泪液碎屑也有改善。

结论

每天两次使用利非司特治疗6个月可改善慢性干眼的体征和症状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/1de1e94757bd/OPTH-13-1033-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/1646421fb6aa/OPTH-13-1033-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/c4dafe34545d/OPTH-13-1033-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/1de1e94757bd/OPTH-13-1033-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/1646421fb6aa/OPTH-13-1033-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/c4dafe34545d/OPTH-13-1033-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becc/6590901/1de1e94757bd/OPTH-13-1033-g0003.jpg

相似文献

1
Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review.在中度至重度症状性干眼症患者中使用lifitegrast进行六个月治疗:一项回顾性病历审查。
Clin Ophthalmol. 2019 Jun 19;13:1033-1037. doi: 10.2147/OPTH.S191635. eCollection 2019.
2
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.利福平眼科溶液 5.0%对比安慰剂治疗干眼疾病:随机 III 期 OPUS-2 研究结果。
Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11.
3
Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity.lifitegrast治疗后干眼症状和体征的纵向变化及其与泪液渗透压的关系。
Clin Ophthalmol. 2019 Mar 28;13:571-579. doi: 10.2147/OPTH.S196593. eCollection 2019.
4
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).利福平格拉司特治疗干眼疾病的 III 期、随机、双盲、安慰剂对照试验(OPUS-3)结果。
Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27.
5
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.利福平眼科溶液 5.0%治疗干眼症:OPUS-1 期 3 研究结果。
Ophthalmology. 2014 Feb;121(2):475-83. doi: 10.1016/j.ophtha.2013.09.015. Epub 2013 Nov 26.
6
Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.5% 利非司特眼药水是一种治疗干眼病安全有效的眼药水:一项系统评价与荟萃分析
J Clin Med. 2022 Aug 26;11(17):5014. doi: 10.3390/jcm11175014.
7
Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease.在美国和加拿大使用lifitegrast眼药水(Xiidra)的真实世界经验:对600例干眼病患者的患者特征、治疗模式及临床疗效的回顾性研究
Clin Ophthalmol. 2021 Mar 8;15:1041-1054. doi: 10.2147/OPTH.S296510. eCollection 2021.
8
Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.5.0% 利福平滴眼液治疗中重度干眼的疗效:两项随机临床试验的事后分析。
JAMA Ophthalmol. 2021 Nov 1;139(11):1200-1208. doi: 10.1001/jamaophthalmol.2021.3943.
9
Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.lifitegrast在三项随机对照试验中治疗干眼病体征和症状的临床疗效。
Curr Med Res Opin. 2016 Oct;32(10):1759-1765. doi: 10.1080/03007995.2016.1210107. Epub 2016 Jul 22.
10
Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.利福平 5%滴眼液治疗干眼的临床疗效。
Eye Contact Lens. 2020 Jan;46 Suppl 1:S20-S24. doi: 10.1097/ICL.0000000000000601.

引用本文的文献

1
A Clinical Evaluation of Lifitegrast Ophthalmic Solution 5% in Symptomatic Contact Lens Wearers.5%利非司特滴眼液对有症状的隐形眼镜佩戴者的临床评估
Clin Ophthalmol. 2025 Aug 29;19:3033-3049. doi: 10.2147/OPTH.S538184. eCollection 2025.
2
Therapeutic Potential of Combined 5% Lifitegrast and Tocopherol Eye Drops in Managing Inflammation and Oxidative Stress in Murine Dry Eye.5% 来氟米特与生育酚联合滴眼液对小鼠干眼炎症和氧化应激的治疗潜力
Pharmaceuticals (Basel). 2025 Jan 1;18(1):38. doi: 10.3390/ph18010038.
3
Lifitegrast in Treatment of Dry Eye Disease-A Practical, Narrative Expert Review.

本文引用的文献

1
TFOS DEWS II Management and Therapy Report.TFOS DEWS II 管理和治疗报告。
Ocul Surf. 2017 Jul;15(3):575-628. doi: 10.1016/j.jtos.2017.05.006. Epub 2017 Jul 20.
2
TFOS DEWS II Definition and Classification Report.TFOS DEWS II 定义与分类报告。
Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. Epub 2017 Jul 20.
3
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).利福平格拉司特治疗干眼疾病的 III 期、随机、双盲、安慰剂对照试验(OPUS-3)结果。
lifitegrast治疗干眼症——实用的专家叙述性综述
J Ophthalmol. 2025 Jan 16;2025:6504111. doi: 10.1155/joph/6504111. eCollection 2025.
4
OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use.OC-01(伐尼克兰溶液)鼻喷雾剂显示,无论年龄、种族、民族和是否使用人工泪液,其效果均具有一致性。
Clin Ophthalmol. 2022 Oct 13;16:3405-3413. doi: 10.2147/OPTH.S383091. eCollection 2022.
5
The Effect of Anti-Inflammatory Topical Ophthalmic Treatments on In Vitro Corneal Epithelial Cells.抗炎性局部眼科治疗对体外角膜上皮细胞的影响。
Transl Vis Sci Technol. 2022 Sep 1;11(9):16. doi: 10.1167/tvst.11.9.16.
6
Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.5% 利非司特眼药水是一种治疗干眼病安全有效的眼药水:一项系统评价与荟萃分析
J Clin Med. 2022 Aug 26;11(17):5014. doi: 10.3390/jcm11175014.
Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27.
4
LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.LFA-1/ICAM-1 相互作用作为干眼病的治疗靶点。
J Ocul Pharmacol Ther. 2017 Jan/Feb;33(1):5-12. doi: 10.1089/jop.2016.0105. Epub 2016 Dec 1.
5
Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.lifitegrast在三项随机对照试验中治疗干眼病体征和症状的临床疗效。
Curr Med Res Opin. 2016 Oct;32(10):1759-1765. doi: 10.1080/03007995.2016.1210107. Epub 2016 Jul 22.
6
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.5.0% 立他司特滴眼液在干眼症患者中的安全性:一项为期1年的多中心随机安慰剂对照研究。
Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803.
7
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.利福平他,一种新型整合素拮抗剂,用于治疗干眼症。
Ocul Surf. 2016 Apr;14(2):207-15. doi: 10.1016/j.jtos.2016.01.001. Epub 2016 Jan 22.
8
Long-term Natural History of Dry Eye Disease from the Patient's Perspective.从患者角度看干眼症的长期自然史
Ophthalmology. 2016 Feb;123(2):425-433. doi: 10.1016/j.ophtha.2015.10.011. Epub 2015 Nov 21.
9
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.利福平眼科溶液 5.0%对比安慰剂治疗干眼疾病:随机 III 期 OPUS-2 研究结果。
Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11.